Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Free Cash Flow (2017 - 2026)

Cogent Biosciences' Free Cash Flow history spans 10 years, with the latest figure at -$87.3 million for Q1 2026.

  • Quarterly Free Cash Flow fell 30.23% to -$87.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$286.3 million through Mar 2026, down 28.48% year-over-year, with the annual reading at -$266.0 million for FY2025, 27.66% down from the prior year.
  • Free Cash Flow came in at -$87.3 million for Q1 2026, down from -$79.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$27.6 million in Q2 2022 to a low of -$87.3 million in Q1 2026.
  • The 5-year median for Free Cash Flow is -$44.4 million (2023), against an average of -$49.6 million.
  • Year-over-year, Free Cash Flow plummeted 153.17% in 2022 and then decreased 0.9% in 2023.
  • Cogent Biosciences' Free Cash Flow stood at -$31.4 million in 2022, then plummeted by 41.47% to -$44.4 million in 2023, then tumbled by 36.65% to -$60.7 million in 2024, then plummeted by 31.76% to -$79.9 million in 2025, then dropped by 9.28% to -$87.3 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Free Cash Flow are -$87.3 million (Q1 2026), -$79.9 million (Q4 2025), and -$64.4 million (Q3 2025).